MENU

Metabolon Awarded US Patent for Determining Metabolic Age of an Individual

09/13/10

Metabolon Awarded US Patent for Determining Metabolic Age of an Individual

RESEARCH TRIANGLE PARK, N.C. (September 13, 2010) — Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announced today the grant of US Patent 7,781,160 entitled “Biomarkers Related to Metabolic Age and Methods Using the Same”.  The USPTO awarded the patent to Metabolon on August 24, 2010.  This is the 12th patent issued to Metabolon. 

As more information regarding the impact of nutrition on health-related issues becomes available and as the population ages, interest in health and nutrition has increased.  The metabolism of an individual changes with age.  Until recently the ability to monitor metabolite changes has been limited to targeted assays.  With the development of metabolomics analysis, changes in metabolites can now be monitored globally in a non-targeted manner.  This metabolomic approach allows a metabolic profile to be determined for a group or an individual.   The patented invention provides biomarkers and methods to determine the metabolic age of an individual.  The ability to determine the metabolite levels of an individual and classify the resulting metabolic profile as positive or negative and then to provide guidance as to how to improve a negative profile will have beneficial effects on the health of an individual. 

Metabolon is the exclusive license holder of the Daouk-Kristal patent family which is comprised of early, pioneering patents and patent applications which provide fundamental IP in the field of metabolomics. Metabolon’s previously issued patents include the use of metabolomics for determining biomarkers for disease, including cancer, metabolic disorders, and neurological disorders such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, depression and schizophrenia, and for evaluating chemical agents for therapeutic effects and toxicity.  Metabolon also owns patents relating to software designed for analyzing metabolomics data.

About Metabolon
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com or contact Matt Zaske at mzaske@metabolon.com or 919-595-2200.